Results 1 to 10 of about 19,651 (218)

Efficacy and safety of cardiac myosin inhibitors for symptomatic hypertrophic cardiomyopathy: a meta-analysis of randomized controlled trials [PDF]

Frontiers in Cardiovascular Medicine
IntroductionHypertrophic cardiomyopathy (HCM) is a common genetic heart disorder. It is characterized by left ventricular hypertrophy and impaired cardiac function, with forms categorized into obstructive (oHCM) and nonobstructive (nHCM).
Madiha Shāh
exaly   +6 more sources

Cardiac Myosin Inhibitors as a Novel Treatment Option for Obstructive Hypertrophic Cardiomyopathy: Addressing the Core of the Matter [PDF]

Journal of the American Heart Association, 2022
Ahmad Masri, Iacopo Olivotto
exaly   +6 more sources

Cardiac Myosin Inhibitors (CMIs) and Surgical Referral in Patients with Hypertrophic Cardiomyopathy. [PDF]

J Cardiovasc Dev Dis
The management of obstructive hypertrophic cardiomyopathy (HCM) has been transformed by the advent of cardiac myosin inhibitors (CMIs), such as mavacamten and aficamten.
Ferraresi B, Nenna A, Jawabra M, Corrado D, Faggiano A, Carugo S, Dominici C, Casali G, Chello M, Lusini M.   +9 more
europepmc   +4 more sources

Cardiac Myosin Inhibitors in the Treatment of Hypertrophic Cardiomyopathy: Clinical Trials and Future Challenges. [PDF]

Biomolecules
Hypertrophic cardiomyopathy (HCM) is a prevalent and often underdiagnosed genetic cardiac disorder characterized by left ventricular hypertrophy and, in many cases, dynamic left ventricular outflow tract obstruction (LVOTO).
Kukowka A, Droździk M.
europepmc   +5 more sources

Efficacy of cardiac myosin inhibitors mavacamten and aficamten in hypertrophic cardiomyopathy: a systematic review and meta-analysis of randomised controlled trials. [PDF]

Open Heart
Background Unlike other suggested therapies, myosin inhibitors have been shown to change the course of hypertrophic cardiomyopathy by altering the contractile mechanics of cardiomyocytes.
Aman A, Akram A, Akram B, Maham M, Bokhari MZ, Akram A, Akram S, Yaqub F.   +7 more
europepmc   +5 more sources

Assessing the Applicability of Cardiac Myosin Inhibitors for Hypertrophic Cardiomyopathy Management in a Large Single Center Cohort [PDF]

Reviews in Cardiovascular Medicine
Background: Cardiac myosin inhibitors (CMIs), including Mavacamten and Aficamten, have emerged as a groundbreaking treatment for hypertrophic cardiomyopathy (HCM).
Ali Amr, Elham Kayvanpour, Christoph Reich   +2 more
exaly   +4 more sources

Cardiac myosin inhibitors: Efficacy, safety and future directions of aficamten in hypertrophic obstructive cardiomyopathy. [PDF]

Egypt Heart J
Background Hypertrophic obstructive cardiomyopathy (HOCM) is a genetic disorder that affects the cardiac myocytes leading to asymmetric hypertrophy of the left ventricle and obstruction of the left ventricular outflow tract (LVOT) with possible risk of ...
Ogieuhi IJ, Ajekiigbe VO, Adeyemi BA, Nwatamole B, Ayodeji KB, Ugiomoh OM, Odeniyi TA, Akingbola A, Iyawe EP, Oladejo OO, Lawal MO, Woldehana NA, Bakare IS, Patience AT, Okoro GC.   +14 more
europepmc   +4 more sources

Cardiac Myosin Inhibitors in Hypertrophic Cardiomyopathy: From Sarcomere to Clinic [PDF]

International Journal of Molecular Sciences
, Takahiro Okumura, Seiya Kato
exaly   +4 more sources

The Efficacy of Cardiac Myosin Inhibitors Versus Placebo in Patients with Symptomatic Hypertrophic Cardiomyopathy

Translation, 2023
Please view the PDF to see the formatted meeting abstract.  
Mohammand Yassen
openalex   +4 more sources

A therapeutic leap: how myosin inhibitors moved from cardiac interventions to skeletal muscle myopathy solutions [PDF]

The Journal of Clinical Investigation
The myosin inhibitor mavacamten has transformed the management of obstructive hypertrophic cardiomyopathy (HCM) by targeting myosin ATPase activity to mitigate cardiac hypercontractility.
Julius Bogomolovas, Ju Chen
openalex   +2 more sources